Your browser doesn't support javascript.
loading
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Boye, Kristina S; Sapin, Hélène; Dong, Wenxiu; Williamson, Suzanne; Lee, Clare J; Thieu, Vivian Thuyanh.
Afiliación
  • Boye KS; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. boye_kristina_secnok@lilly.com.
  • Sapin H; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Dong W; TechData Service Company, King of Prussia, PA, USA.
  • Williamson S; Greenwich HE&OR Ltd., London, UK.
  • Lee CJ; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Thieu VT; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Diabetes Ther ; 14(11): 1867-1887, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37668888
Limited data exist about the relationship between quality of life (QoL) and changes in clinical measures, for example management of blood sugar levels and weight, in people with type 2 diabetes. We explored the associations between glucose and weight loss targets achieved and QoL outcomes reported by adults treated with tirzepatide, the first glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for the treatment of people with type 2 diabetes, using data from SURPASS-1 to -5 Phase 3 clinical trials.Five questionnaires, developed to evaluate patients' health-related QoL, were completed by patients at the beginning and end of the clinical trials, which was after 40 weeks for SURPASS-1, -2 and -5 and after 52 weeks for SURPASS-3 and -4, or when the person left the trial if this was before the official end. These questionnaires were: EQ-5D-5L (SURPASS-1 to -5); Impact of Weight on Self-Perception questionnaire (SURPASS-1 to -5); Ability to Perform Physical Activities of Daily Living (SURPASS-1 to -5); Diabetes Treatment Satisfaction Questionnaire change (SURPASS-2 to -5); and Impact of Weight on Quality of Life­Lite Clinical Trials Version (SURPASS-2 only).Overall, achievement of lower glucose targets or higher percentage of body weight losses were each associated with greater improvements in QoL. Achievement of lower glucose targets in combination with greater weight loss was generally associated with the highest health-related QoL ratings.Tirzepatide treatment may allow a high proportion of people with type 2 diabetes to achieve lower glucose levels and higher weight loss, enabling improved health-related QoL.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Diabetes Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Diabetes Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos